Newsk4xqd2025-02-17T14:10:32+00:00

News

How to market a drug in France? Centralized Marketing Authorization and other cases
Continue reading
Early access and compassionate use: making a drug available when not authorized in France
Continue reading
What are the EMA’s timelines for the standard and accelerated procedures?
Continue reading
Understanding the differences between the FDA and the EMA: strategic implications for market access
Continue reading
Pharmaceutical patents: how to protect the intellectual property of a healthcare innovation?
Continue reading
Requirements for compliant manufacturing of biotechnological products
Continue reading
How to manage regulatory variations of a Marketing Authorisation (MA)?
Continue reading
What are the upcoming changes for biosimilar medicines in the European Union?
Continue reading
Strategies to reduce drug development time
Continue reading
What are the EMA’s requirements for clinical trials?
Continue reading
What are the financing options for a biotechnology startup?
Continue reading
Marketing Authorization (MA) for a New Drug
Continue reading